Status:
COMPLETED
Molecular Genetic, Host-derived and Clinical Determinants of Long-term Survival in Glioblastoma
Lead Sponsor:
European Organisation for Research and Treatment of Cancer - EORTC
Conditions:
Glioblastoma
Eligibility:
All Genders
18+ years
Brief Summary
This pro - and retrospective multicenter clinical epidemiological study studies the molecular genetic, host-derived and clinical determinants of glioblastoma patients with an overall survival of more ...
Eligibility Criteria
Inclusion
- Age \> 18 years at diagnosis
- Histopathological diagnosis of glioblastoma (reference histology available) and
- Survival \>5 years from diagnosis
- Availability of tumor tissue from initial glioblastoma diagnosis (FFPE or fresh-frozen) to validate the diagnosis centrally.
- Signed consent form (living patients) or ethics approval for anonymous data collection in case of retrospective analysis of deceased patients
Exclusion
- Not applicable
Key Trial Info
Start Date :
July 5 2015
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 18 2023
Estimated Enrollment :
599 Patients enrolled
Trial Details
Trial ID
NCT03770468
Start Date
July 5 2015
End Date
August 18 2023
Last Update
March 8 2024
Active Locations (27)
Enter a location and click search to find clinical trials sorted by distance.
1
Dana-Farber Cancer Institute & Harvard Medical School
Boston, Massachusetts, United States, 02115-5450
2
Universitaetsklinikum Wien - AKH uniklinieken
Vienna, Austria, 1090
3
Hopitaux Universitaires Bordet-Erasme
Brussels, Belgium, 1070
4
CHU Lyon - Hopital neurologique Pierre Wertheimer
Bron, France, 69677